Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".
Name:
Comment article.pdf
Embargo:
2219-07-17
Size:
1.202Mb
Format:
PDF
Request:
Main article
Authors
Perrotti, DaniloAgarwal, Anupriya
Lucas, Claire
Narla, Goutham
Neviani, Paolo
Odero, Maria D.
Ruvolo, Peter P.
Verrills, Nicole M.
Publication Date
2019-07-17
Metadata
Show full item recordAbstract
LB100 does not sensitize CML stem cells to tyrosine kinase inhibitor–induced apoptosis.Citation
Perrotti, D., Agarwal, A., Lucas, C., Narla, G., Neviani, P., Odero, M., . . . Verrills, N. (2019). Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia". Science Translational Medicine, 11(501) doi:10.1126/scitranslmed.aau0416Journal
Science Translational MedicineType
articleISSN
1946-6234EISSN
1946-6242ae974a485f413a2113503eed53cd6c53
10.1126/scitranslmed.aau0416